This document provides a detailed overview of JSON validation, data cleaning, and structuring, focusing on specific field requirements and the implementation of schema.org for FAQs.

Met Police chief Sir Mark Rowley says the force is looking at "an online claim of responsibility by an Islamist group" ...

Police say they are looking for three suspects after the London Fire Brigade were called to Golders Green at around 01:40 GMT ...

ATTR-CM often requires a team of healthcare providers, including cardiologists, specialists, and primary care doctors. Caregivers play an important role in coordinating appointments, sharing ...

转甲状腺素蛋白淀粉样变性（ATTR）是一类罕见的多器官损伤疾病，因体内转甲状腺素蛋白（TTR）异常折叠沉积，累及神经、心脏等关键器官，患者常面临认知低、诊疗难的困境。香港登越药业深耕罕见病创新药领域，为大家科普这款针对性创新药物——Onpattro ...

Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...

Caring for someone with ATTR amyloidosis can be physically and emotionally demanding. To reduce the chances of burnout, caregivers should also prioritize their own well-being. Factors such as ...

A time delay of 14 months on average still exists between the onset of clinical manifestations and the initial suspicion of cardiac amyloidosis. Despite advances in noninvasive diagnostic techniques, ...

Los Angeles Dodgers right-hander Roki Sasaki was hit hard and had a tough time finding the strike zone in his first spring ...

Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...

ATTR-CM can be a life-changing diagnosis, and if youre an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

NEW YORK – Intellia Therapeutics on Tuesday said that the US Food and Drug Administration has lifted the clinical hold on one of two trials in which the company is evaluating its in vivo CRISPR ...